Hansa Biopharma: Sales support, easing funding pressure as the strategic review continues - Redeye

Hansa is better positioned to support its main value drivers, engage in strategic priorities, and potentially extend the number of commercial and clinical partners over the next 6-12 months. We expect a slight positive reaction, even if the 76% quarterly sales growth was softer.

Länk till analysen i sin helhet: https://www.redeye.se/research/1118775/hansa-biopharma-sales-support-easing-funding-pressure-as-the-strategic-review-continues?utm_source=finwire&utm_medium=RSS